Recurrent Rectal Cancer

Oncology
0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Carbon Ion RadiotherapyN/A1 trial
Active Trials
NCT01528683Completed14Est. May 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Heidelberg PharmaCarbon Ion Radiotherapy

Clinical Trials (1)

Total enrollment: 14 patients across 1 trials

NCT01528683Heidelberg PharmaCarbon Ion Radiotherapy

Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent Rectal Cancer

Start: Dec 2012Est. completion: May 201814 patients
N/ACompleted

Related Jobs in Oncology

Medical Writer

SystImmune
8h ago
$80K - $130K/yr

Director of Clinical Science

SystImmune
8h ago
$180K - $230K/yr

Clinical Scientist

SystImmune
8h ago
$80K - $120K/yr

Scientist/Senior Scientist, Clinical Pathology & IHC

SystImmune
8h ago
$90K - $140K/yr

Study Startup Specialist

SystImmune
8h ago
$70K - $95K/yr

Senior Clinical Research Associate

SystImmune
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Breast Cancer(632)Prostate Cancer(401)Non-small Cell Lung Cancer(388)Multiple Myeloma(363)Cancer(259)Advanced Solid Tumors(230)Acute Myeloid Leukemia(210)Neoplasms(207)Lung Cancer(175)Colorectal Cancer(174)